查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924738

核醫放射性藥物市場（依產品類型、放射性核種類型、最終用戶和應用分類）－2026-2032年全球預測

Radiopharmaceuticals in Nuclear Medicine Market by Product Type, Radionuclide, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年核醫放射性藥物市值為97.8億美元，預計2026年將成長至106.9億美元，年複合成長率為10.37%，到2032年將達到195.2億美元。

關鍵市場統計數據
基準年 2025 97.8億美元
預計年份：2026年 106.9億美元
預測年份 2032 195.2億美元
複合年成長率 (%) 10.37%

本文簡要介紹了分子影像和標靶放射性核素治療如何重新定義現代醫學的臨床路徑和生態系統動態。

放射性藥物已從專科中心使用的特定示蹤劑轉變為現代診斷和治療流程中不可或缺的組成部分。本文將基礎科學置於臨床應用的背景下，重點闡述了正子斷層掃描 (PET) 和單光子發射電腦斷層掃描 (SPECT) 如何與標靶放射療法（可將細胞毒性藥物直接輸送到病變組織）同步過程。分子影像與治療的融合重塑了診斷流程，並使伴隨診斷能夠指導精準治療，從而增強了放射性核素干預在腫瘤學、神經病學和心臟病學領域的作用。

概述重塑診斷和治療放射性藥物的生產、監管和臨床應用的主要變革性轉變

放射性藥物領域正經歷著一場由技術創新、監管成熟和臨床範式轉移所驅動的變革浪潮。放射化學和發生器技術的進步擴大了短壽命同位素的獲取途徑，並實現了分散式生產模式，加速了臨床試驗的招募和臨床應用。同時，α發射體療法的興起帶來了新的療效和安全性特徵，需要相應的全新臨床管理策略、專門的通訊協定和個人化的報銷機制。因此，放射性同位素的可用性如今已成為醫療機構工作流程和資本規劃的核心營運限制因素。

深入分析 2025 年美國關稅調整對放射性藥物供應鏈、籌資策略和物流的影響。

2025年公佈的關稅調整給支持放射性藥物研發和分銷的國際供應鏈帶來了實際壓力。前驅化學品、特殊試劑和部分輔助設備的進口關稅提高，增加了許多製造商的到岸成本，迫使採購團隊重新評估籌資策略和庫存政策。為此，生產計畫負責人已加大力度，盡可能加快關鍵投入品的在地採購，投資於雙重採購安排，並重新談判供應商合約以降低成本波動。

全面的細分分析表明，產品類型、臨床應用案例、放射性同位素、最終用戶和分銷模式各自構成不同的策略要務。

放射性藥物市場的細分凸顯了不同產品類型、臨床應用、放射性同位素、終端用戶和分銷管道需要不同的策略應對措施。產品差異化涵蓋了用於PET和SPECT成像的診斷劑以及依賴α和BETA發射體的治療劑。診斷性PET產品主要基於氟-18和鎵-68平台，而SPECT應用則繼續依賴碘-123和Technetium-99m。治療產品組合包括α發射體，例如錒-225和鐳-223，以及BETA發射體，例如碘-131、鎦-177和釔-90。這種多樣性在從研發到商業化的每個階段都帶來了不同的監管、生產和物流要求。

從區域觀點出發，探討基礎設施、臨床應用和策略投資如何影響美洲、歐洲、中東和非洲以及亞太地區的市場准入決策。

區域趨勢對放射性藥物的研發、應用和基礎設施投資具有決定性影響。在美洲，成熟的臨床需求、先進的影像網路以及不斷擴充的治療產品線共同推動了商業模式、報銷談判和整合式醫療路徑的創新。在此背景下，研究型醫院、契約製造和診斷中心之間的合作正在加速從臨床試驗到常規臨床應用的轉化，同時法規結構也在不斷發展以適應新的治療方法。

來自主要企業和機構的真知灼見，重點介紹了推動競爭優勢的策略投資、合作夥伴生態系統和製造能力。

主要企業和機構正透過投資同位素生產、放射化學平台和臨床開發項目，重塑放射性藥物產業的格局。領先的商業機構正在拓展其服務組合，提供涵蓋生產、品質保證和分銷的端到端解決方案，從而降低醫院系統和研究網路的複雜性。同時，學術機構和專科醫院正透過研究者主導的臨床研究和早期臨床試驗，提供關鍵的臨床檢驗，幫助降低新型治療方法的風險。

為領導者提供具體策略建議，以加強供應韌性、加速臨床檢驗並確保放射性藥物的報銷途徑。

為了創造放射性藥物的長期價值，產業領導者應優先投資於增強供應鏈韌性、提高監管準備度和累積臨床證據。加強區域生產能力並採用分散式產生器模式可以降低跨境物流和關稅波動帶來的風險。在進行基礎設施投資的同時，各機構應與學術機構和專科診所建立正式的策略合作夥伴關係，以加速轉化研究並產生真實世界證據，從而支持藥品報銷和擴大臨床應用。

對依證調查方法進行清晰闡述，該方法結合了相關人員訪談、監管審查和技術整合，以確保研究結果的可靠性。

該報告的調查方法整合了一手和二手訊息，旨在為放射性藥物行業提供嚴謹且基於證據的觀點。一手資訊包括對放射化學家、臨床研究人員、醫院藥屋主任和供應鏈高管的結構化訪談，以及與監管和報銷專家的諮詢。與這些相關人員的討論提供了有關生產限制、臨床應用促進因素和最佳營運實踐的定性背景資訊。

簡明扼要的結論總結了技術進步、營運複雜性和相關人員合作將如何決定放射性藥物領域未來的成功。

結論部分概述了科學創新、供應鏈趨勢以及不斷變化的監管和報銷環境如何共同塑造放射性藥物領域的機會和風險。診斷和治療方法正在精準醫療應用中融合，這需要對生產、臨床檢驗和分銷基礎設施進行協調投資。能夠將生產可靠性與臨床證據產生和與支付方的合作相結合的企業，將獲得策略差異化優勢。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 核醫放射性藥物市場（依產品類型分類）

  • 診斷用放射性藥物
    • PET
      • 氟-18放射性藥物
      • 鎵-68放射性藥物
    • SPECT
      • 碘-123放射性藥物
      • Technetium-99m放射性藥物
  • 治療性放射性藥物
    • 阿爾法發射體
      • 錒-225
      • 鐳-223
    • BETA射線放射體
      • 碘-131
      • 鎦-177
      • 釔-90

9. 依放射性核種類型分類的核醫放射性藥物市場

  • 氟18
  • 碘-131
  • 鎦-177
  • Technetium-99m
  • 釔-90

第10章 核醫放射性藥物市場（依最終用戶分類）

  • 學術研究機構
  • 醫院和診所
    • 私人診所
    • 公立醫院
  • 醫學影像檢查中心
    • 影像檢查中心
    • 專業治療中心

第11章 核醫放射性藥物市場（依應用領域分類）

  • 腦部影像
    • PET腦部藥物
    • SPECT腦部藥物
  • 心臟病學
    • 灌注影像
    • 可行性成像
  • 腫瘤學
    • PET影像
      • 氟-18放射性藥物
      • Technetium-99m放射性藥物
    • 治療
      • α粒子療法
      • BETA射線療法

第12章 核醫放射性藥物市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 核醫放射性藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國核醫放射性藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國核醫放射性藥物市場

第16章：中國核醫放射性藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bracco Imaging SpA
  • BWXT Medical Ltd.
  • Cardinal Health, Inc.
  • Clarity Pharmaceuticals Pty Ltd
  • Curium Pharma SAS
  • Eckert & Ziegler Strahlen-und Medizintechnik AG
  • Eli Lilly and Company
  • GE HealthCare, Inc.
  • ITM Isotope Technologies Munich SE
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • NorthStar Medical Radioisotopes LLC
  • Novartis AG
  • PharmaLogic Holdings Corp.
  • RayzeBio, Inc.
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited
Product Code: MRR-7A380DA7C469

The Radiopharmaceuticals in Nuclear Medicine Market was valued at USD 9.78 billion in 2025 and is projected to grow to USD 10.69 billion in 2026, with a CAGR of 10.37%, reaching USD 19.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.78 billion
Estimated Year [2026] USD 10.69 billion
Forecast Year [2032] USD 19.52 billion
CAGR (%) 10.37%

A concise introduction to how molecular imaging and targeted radionuclide therapies are redefining clinical pathways and ecosystem dynamics in modern healthcare

Radiopharmaceuticals have transitioned from niche tracers used in specialized centers to integral components of contemporary diagnostic and therapeutic care pathways. This introduction frames the foundational science through the lens of clinical adoption, emphasizing how positron emission tomography and single photon emission computed tomography have matured alongside targeted radiotherapeutics that deliver cytotoxic payloads directly to pathologic tissues. The convergence of molecular imaging and molecular therapy has reshaped diagnostic algorithms and enabled companion diagnostics that guide precision treatments, thereby elevating the role of radionuclide-based interventions across oncology, neurology, and cardiology.

Beyond clinical utility, the ecosystem that supports radiopharmaceuticals encompasses isotope production, radiochemistry, regulatory oversight, and complex logistics that preserve radionuclide integrity. As manufacturing technologies evolve and therapeutic alpha and beta emitters advance into later-stage clinical development, stakeholders must adapt to shorter supply chains, higher regulatory scrutiny, and novel reimbursement conversations. This introduction sets the stage for deeper analysis by outlining the scientific trajectory and commercial context that propel the radiopharmaceuticals landscape forward.

An overview of the major transformative shifts reshaping production, regulation, and clinical adoption across diagnostic and therapeutic radiopharmaceuticals

The radiopharmaceuticals sector is undergoing transformative shifts driven by technological innovation, regulatory maturation, and changing clinical paradigms. Advances in radiochemistry and generator technologies have expanded access to short-lived isotopes and enabled decentralized production models, which in turn accelerate trial enrollment and clinical adoption. Meanwhile, the rise of alpha-emitter therapeutics has introduced new efficacy and safety profiles that demand fresh clinical management strategies, specialized handling protocols, and tailored reimbursement frameworks. As a result, institutional workflows and capital planning now integrate isotope availability as a core operational constraint.

Parallel to technological shifts, regulatory pathways are adapting to accommodate companion diagnostics and novel therapeutic constructs while emphasizing patient safety and manufacturing traceability. Payer engagement is similarly evolving, with value-based discussions increasingly focused on downstream clinical and economic outcomes rather than acquisition cost alone. These converging forces are driving collaborations across academic centers, contract manufacturers, and commercial sponsors, thereby reshaping competitive dynamics and creating opportunities for integrated service offerings that span production, delivery, and clinical utilization.

A detailed analysis of how the 2025 United States tariff adjustments reshaped supply chains, procurement strategies, and logistics for radiopharmaceuticals

Tariff changes announced in 2025 introduced tangible pressures across international supply chains that support radiopharmaceutical development and distribution. Increased import duties on precursor chemicals, specialized reagents, and some ancillary equipment raised landed costs for many manufacturers, compelling procurement teams to revisit sourcing strategies and inventory policies. In turn, production planners accelerated efforts to localize critical inputs where feasible, invest in dual-sourcing arrangements, and renegotiate supplier contracts to mitigate cost volatility.

Logistics and cold-chain providers faced higher cross-border handling fees that complicated time-sensitive deliveries of short-lived isotopes, prompting a renewed emphasis on regional distribution networks and on-site generator solutions. Clinical trial sponsors and hospital networks felt downstream effects as operational budgets absorbed incremental transport and material expenses, which necessitated strategic reprioritization of pipeline activities and capital projects. In response, industry participants pursued policy engagement with regulators and trade authorities to secure exemptions for clinical and research materials, while concurrently exploring manufacturing innovations and public-private partnerships to sustain access and control costs.

Comprehensive segmentation insights revealing how product types, clinical use cases, radionuclides, end users, and distribution models create distinct strategic imperatives

Segmenting the radiopharmaceuticals landscape clarifies how product types, clinical applications, radionuclides, end users, and distribution channels each demand distinct strategic responses. Product differentiation spans diagnostic agents used in PET and SPECT imaging and therapeutic agents that rely on alpha and beta emitters; diagnostic PET offerings emphasize fluorine-18 and gallium-68 platforms, while SPECT applications remain anchored to iodine-123 and technetium-99m chemistry, and therapeutic portfolios include actinium-225 and radium-223 among alpha options and iodine-131, lutetium-177, and yttrium-90 among beta emitters. This diversity drives separate regulatory, manufacturing, and logistical requirements across development and commercialization pathways.

Clinical applications further segment demand by brain imaging, cardiology, and oncology, with brain agents differentiated into PET and SPECT modalities, cardiology encompassing perfusion and viability imaging with specific tracer classes, and oncology spanning both diagnostic PET imaging with fluorine-18 and technetium-99m tracers and targeted therapy using alpha and beta emitter constructs. Radionuclide-focused segmentation highlights unique handling and production needs for fluorine-18, iodine-131, lutetium-177, technetium-99m, and yttrium-90. End-user segmentation identifies academic and research institutions, hospitals and clinics including private and public facilities, and imaging centers that range from diagnostic-only operations to specialty therapy centers. Distribution channels bifurcate into direct sales and indirect sales through distributors and wholesalers, with wholesaler networks further differentiated across national and regional players. Together, these segmentation lenses inform tailored product design, go-to-market strategies, and investment in manufacturing and distribution infrastructure.

A regional perspective on infrastructure, clinical adoption, and strategic investment across the Americas, EMEA, and Asia-Pacific that shapes market entry decisions

Regional dynamics exert a decisive influence on radiopharmaceutical development, adoption, and infrastructure investment. The Americas combine mature clinical demand, advanced imaging networks, and a growing therapeutic pipeline, which encourages innovation in commercial models, reimbursement negotiation, and integrated care pathways. In this environment, partnerships between research hospitals, contract manufacturers, and diagnostic centers accelerate translation from clinical trials to routine clinical use while regulatory frameworks continue to evolve to accommodate new modalities.

Europe, the Middle East, and Africa present a heterogeneous mix of capability and demand: some markets exhibit strong regulatory harmonization and established nuclear medicine services, while others focus on building capacity through regional manufacturing hubs and training initiatives. In these regions, cross-border collaborations and centralized isotope producers play a central role in widening access. The Asia-Pacific region demonstrates rapid capacity expansion driven by rising healthcare investment, increasing oncology burden, and strategic public-private initiatives to localize isotope production and radiopharmacy expertise. Each region's trajectory informs decisions on where to prioritize manufacturing investments, clinical partnerships, and market-entry sequencing.

Key company and institutional insights highlighting strategic investments, partner ecosystems, and manufacturing capabilities that drive competitive advantage

Leading companies and institutional players shape the radiopharmaceuticals landscape through investments in isotope production, radiochemistry platforms, and clinical development programs. Key commercial entities have expanded their service portfolios to offer end-to-end solutions that combine manufacturing, quality assurance, and distribution, thereby reducing complexity for hospital systems and research networks. At the same time, academic centers and specialized hospitals contribute critical clinical validation through investigator-initiated studies and early-phase trials that de-risk novel therapeutic constructs.

Strategic alliances between technology providers, contract manufacturing organizations, and clinical sponsors have become instrumental in scaling production of both diagnostic tracers and therapeutic agents. These partnerships frequently target capacity expansion, regulatory filings, and optimized logistics for short-lived isotopes. Investors and corporate development teams have also prioritized capabilities that enable rapid translation from radiochemistry advances to GMP-compliant manufacturing, acknowledging that differentiated production and distribution capabilities will determine competitive positioning in both diagnostic and therapeutic market segments.

Actionable strategic recommendations for leaders to strengthen supply resilience, accelerate clinical validation, and secure reimbursement pathways for radiopharmaceuticals

Industry leaders should prioritize investments that enhance supply resilience, regulatory readiness, and clinical evidence generation to capture long-term value in radiopharmaceuticals. Strengthening regional production capacity and adopting decentralized generator models can mitigate the risks associated with cross-border logistics and tariff volatility. Alongside infrastructure investment, organizations should formalize strategic partnerships with academic centers and specialty clinics to accelerate translational research and generate real-world evidence that supports reimbursement and broader clinical adoption.

Operational excellence in radiopharmacy processes, cold-chain logistics, and quality systems will differentiate providers as therapeutic radiopharmaceuticals enter later-stage development. Companies should also engage proactively with regulatory bodies and payers to shape pragmatic pathways for approval and reimbursement that reflect therapeutic value over time. Finally, building internal commercial capabilities that educate clinicians and streamline patient access will be essential to converting clinical potential into consistent utilization across diagnostic and therapeutic indications.

A clear explanation of the evidence-based research methodology combining stakeholder interviews, regulatory review, and technical synthesis to ensure robust insights

The research methodology for this report synthesizes primary and secondary inputs to deliver a rigorous, evidence-based perspective on the radiopharmaceuticals landscape. Primary inputs include structured interviews with radiochemists, clinical investigators, hospital pharmacy directors, and supply chain executives, as well as consultations with regulatory specialists and reimbursement experts. These stakeholder discussions provide qualitative context on manufacturing constraints, clinical adoption drivers, and operational best practices.

Secondary research integrates peer-reviewed literature, regulatory guidance documents, technical standards for radiopharmacy, and company disclosures to validate findings and identify industry trends. Data were triangulated across sources to ensure consistency and to highlight areas of divergence that warrant further investigation. The methodology emphasizes transparency in assumptions, a focus on operational and clinical drivers rather than purely commercial metrics, and iterative validation with subject-matter experts to refine conclusions and recommendations.

A concise conclusion synthesizing how technological progress, operational complexity, and stakeholder alignment determine future success in radiopharmaceuticals

The conclusion synthesizes how scientific innovation, supply chain dynamics, and evolving regulatory and reimbursement environments collectively shape opportunities and risks in radiopharmaceuticals. Diagnostic and therapeutic modalities are converging around precision applications that demand coordinated investment in production, clinical validation, and distribution infrastructure. Strategic differentiation will accrue to organizations that can marry manufacturing reliability with clinical evidence generation and payer engagement.

Looking forward, the sector will continue to balance rapid technological progress with operational complexity, requiring adaptive strategies that prioritize patient access and safety. Stakeholders who align commercial plans with investments in decentralized production, quality systems, and strategic partnerships will be best positioned to translate advances in radiochemistry and targeted therapies into sustainable clinical and commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radiopharmaceuticals in Nuclear Medicine Market, by Product Type

  • 8.1. Diagnostic Radiopharmaceuticals
    • 8.1.1. PET
      • 8.1.1.1. Fluorine-18 Radiopharmaceuticals
      • 8.1.1.2. Gallium-68 Radiopharmaceuticals
    • 8.1.2. SPECT
      • 8.1.2.1. Iodine-123 Radiopharmaceuticals
      • 8.1.2.2. Technetium-99m Radiopharmaceuticals
  • 8.2. Therapeutic Radiopharmaceuticals
    • 8.2.1. Alpha Emitter
      • 8.2.1.1. Actinium-225
      • 8.2.1.2. Radium-223
    • 8.2.2. Beta Emitter
      • 8.2.2.1. Iodine-131
      • 8.2.2.2. Lutetium-177
      • 8.2.2.3. Yttrium-90

9. Radiopharmaceuticals in Nuclear Medicine Market, by Radionuclide

  • 9.1. Fluorine-18
  • 9.2. Iodine-131
  • 9.3. Lutetium-177
  • 9.4. Technetium-99m
  • 9.5. Yttrium-90

10. Radiopharmaceuticals in Nuclear Medicine Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Hospitals & Clinics
    • 10.2.1. Private Clinics
    • 10.2.2. Public Hospitals
  • 10.3. Imaging Centers
    • 10.3.1. Diagnostic Imaging Centers
    • 10.3.2. Specialty Therapy Centers

11. Radiopharmaceuticals in Nuclear Medicine Market, by Application

  • 11.1. Brain Imaging
    • 11.1.1. PET Brain Agents
    • 11.1.2. SPECT Brain Agents
  • 11.2. Cardiology
    • 11.2.1. Perfusion Imaging
    • 11.2.2. Viability Imaging
  • 11.3. Oncology
    • 11.3.1. PET Imaging
      • 11.3.1.1. Fluorine-18 Radiopharmaceuticals
      • 11.3.1.2. Technetium-99m Radiopharmaceuticals
    • 11.3.2. Therapy
      • 11.3.2.1. Alpha Emitter Therapy
      • 11.3.2.2. Beta Emitter Therapy

12. Radiopharmaceuticals in Nuclear Medicine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Radiopharmaceuticals in Nuclear Medicine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Radiopharmaceuticals in Nuclear Medicine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Radiopharmaceuticals in Nuclear Medicine Market

16. China Radiopharmaceuticals in Nuclear Medicine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Actinium Pharmaceuticals, Inc.
  • 17.6. AstraZeneca plc
  • 17.7. Bayer AG
  • 17.8. Bracco Imaging S.p.A.
  • 17.9. BWXT Medical Ltd.
  • 17.10. Cardinal Health, Inc.
  • 17.11. Clarity Pharmaceuticals Pty Ltd
  • 17.12. Curium Pharma SAS
  • 17.13. Eckert & Ziegler Strahlen- und Medizintechnik AG
  • 17.14. Eli Lilly and Company
  • 17.15. GE HealthCare, Inc.
  • 17.16. ITM Isotope Technologies Munich SE
  • 17.17. Jubilant Pharmova Limited
  • 17.18. Lantheus Holdings, Inc.
  • 17.19. NorthStar Medical Radioisotopes LLC
  • 17.20. Novartis AG
  • 17.21. PharmaLogic Holdings Corp.
  • 17.22. RayzeBio, Inc.
  • 17.23. Siemens Healthineers AG
  • 17.24. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY GALLIUM-68 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY GALLIUM-68 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY GALLIUM-68 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-123 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-123 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-123 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACTINIUM-225, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACTINIUM-225, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIUM-223, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIUM-223, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY YTTRIUM-90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECIALTY THERAPY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECIALTY THERAPY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECIALTY THERAPY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET BRAIN AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET BRAIN AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET BRAIN AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT BRAIN AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT BRAIN AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT BRAIN AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PERFUSION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PERFUSION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PERFUSION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY VIABILITY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY VIABILITY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY VIABILITY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY FLUORINE-18 RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY TECHNETIUM-99M RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ALPHA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BETA EMITTER, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY IMAGING CENTERS, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY BRAIN IMAGING, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY PET IMAGING, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA RADIOPHARMACEUTICALS IN NUCLEAR MEDICINE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC RADIOPHARMACEUTICALS IN NUCLEAR MEDICIN